title: Elevated plasma chromogranin-A concentrations in prostatic carcinoma.
abstract: Chromogranin-A is considered a sensitive immunohistochemical tissue marker in neuroendocrine prostatic carcinoma. We report that the plasma chromogranin-A level was elevated in 48% of 25 patients with stage D2 prostate cancer, and suggest that this marker can be used to monitor the clinical course of these patients.
authors.affiliation: Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030.
authors.forename: D
authors.initials: D
authors.lastname: Kadmon
authors.forename: T C
authors.initials: TC
authors.lastname: Thompson
authors.forename: G R
authors.initials: GR
authors.lastname: Lynch
authors.forename: P T
authors.initials: PT
authors.lastname: Scardino
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D002277:Carcinoma / Q000097:blood*; D053379:Chromogranin A; D002864:Chromogranins / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000097:blood*; D011863:Radioimmunoassay
chemical_list: D015415:Biomarkers; C506150:CHGA protein, human; D053379:Chromogranin A; D002864:Chromogranins